• 대한의용생체공학회:의공학회지
• /
• 제24권4호
• /
• pp.319-328
• /
• 2003

본 논문은 광역학적 암치료를 위한 광원장치의 개발로서 반도체 다이오드 레이저를 이용한 의료용 레이저 시스템의 개발이 목적이다. 광역학적 암 치료에서 이상적인 광원장치는 초점크기를 조절할 수 있으면서 발산하지 않는 균일한 빛과 특정 파장대의 안정성을 갖는 것이다. 본 연구에서는 이러한 점을 고려하여 635nm 파장대의 다이오드 공진기를 이용하였으며, 개발된 레이저 시스템은 제어장치를 사용하여 정교하고 안정적인 출력을 가지도록 하였으며, 시스템은 사용자의 편리성을 고려하여 소형화하였다. 다이오드 레이저시스템의 펄스 형태의 발진모드에서는 초기의 돌입전류에 의해 공진기를 파손시킬 수 있으므로 본 연구에서는 이러한 현상을 회로적으로 보완하여 msec 단위로 on/off 할 경우에도 공진기에 전혀 손상을 입히지 않도록 설계를 하였다. 임상의가 편리하게 방사시간을 설정하고, 연속출력. 펄스. 버스트 펄스, 슈퍼펄스를 방사할 수 있도록 고안하여. 다양한 암조직의 상태에 따라 치료할 수 있도록 구현하였다. 실험결과 레이저의 출력은 입력전류와 시간에 따라 10mW에서 300mW 까지 선형적으로 증가함을 보였다. 개발된 광역학적 레이저 시스템은 고속제어가 가능하고 정 전류 제어와 효과적인 냉각 제어를 통해 안정적으로 정확하게 출력할 수 있었다.

• 한국방사선학회논문지
• /
• 제15권7호
• /
• pp.935-942
• /
• 2021

호흡에 의한 체내 장기의 불수의적 움직임은 방사선 치료 및 진단의 결과에 큰 영향을 주는 요소이다. 본 논문에서는 호흡에 따른 장기 또는 종양의 움직임을 모사하기 위한 움직임 팬텀을 제작하고 다양한 호흡모사 조건에서 ¹⁸F-FDG PET 스캔 영상을 획득하여 호흡에 따른 종양의 움직임 범위와 종양의 크기에 따른 인공물의 수준 및 표준섭취계수 최대값(maximum standardized uptake value, SUVmax)를 분석하였다. 운영체계로 윈도우 CE(Windows CE) 6.0 기반으로 전동액추에이터, 전동액추에이터 포지셔닝 드라이버, PLC(Programmable Logic Controller)을 이용한 위치 및 속도 조절 모듈은 이동거리 0-5 cm와 왕복이동 10회, 15회, 20회에서 정상적으로 동작하였다. 지연시간 100분에서 구의 지름 10, 13, 17, 22, 28, 37mm일 때 각각 80.4, 99.5, 107.9, 113.1, 128.0, 124.8%로 측정되었다. 이동거리가 같을 때 호흡수에 따른 차이는 미미하였다. 호흡수를 20회 하고 이동거리를 1 cm, 2 cm, 3 cm, 5 cm일 때 구의 지름이 10, 13, 17, 22, 28, 37 mm에서 이동거리가 길어질수록 구의 크기가 작은 것 부터영상의 구분 능력이 저하되었다. 정지영상에 비하여 이동거리를 5 cm로 하였을 때, 표준섭취계수의 최대값은 구의 지름이 10, 13, 17, 22, 28, 37 mm에서 각각 18.0%, 23.7%, 29.3%, 38.4%, 49.0%, 67.4%이었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권7호
• /
• pp.3403-3408
• /
• 2012

The molecular mechanisms involved in the progression of clear cell renal cell carcinomas (ccRCCs) are still unclear. The aim of this study was to analyse the relationships between expression of RALYL and clinical characteristics. In 41 paired samples of ccRCCs and adjacent normal tissues, we used real-time qPCR to evaluate the expression of RALYL mRNA. RALYL protein levels were determined in 146 samples of ccRCC and 37 adjacent normal tissues by immunohistochemistry. Statistical analysis was used to explore the relationships between expression of RALYL and the clinical characteristics (gender, age, tumor size, T stage, N stage, M stage, survival times and survival outcome) in ccRCC. In addition, these patients were follow-up period 64 months (range: 4~116months) to investigate the influence on prognosis. We found significantly differences between ccRCC tissues and normal tissues (p<0.001, paired-sample t test) in mRNA levels of RALYL. Immunohistochemistry analyses in 146 ccRCC samples and 37 adjacent normal tissues showed significantly lower RALYL protein levels in ccRCC samples (${\chi}^2$-test, p<0.001), inversely correlating with tumour size (p=0.024), T stage (0.005), N stage (p<0.001) as well as M stage (p=0.019), but not age (p=0.357) and gender (p=0.348). Kaplan-Meier survival analysis demonstrated that people with lower level of RALYL expression had a poorer survival rate than those with a higher level of RALYL expression, significantly different by the log-rank test (p=0.011). Cox regression analysis indicated that RALYL expression (p=0.039), N stage (p=0.008) and distant metastasis (p<0.001) were independent prognosis factors for the overall survival of ccRCC patients. We demonstrated that the expression of RALYL was significantly low in ccRCC and correlated with a poor prognosis in a large number of clinical samples. Our findings showed that RALYL may be a potential therapeutic target as well as a poor prognostic factor.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7825-7829
• /
• 2015

Background: Egypt has the highest prevalence of HCV infection in the world (~14.7%). Around 10-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. The incidence of HCC is expected to grow in the next two decades, largely due to HCV related cirrhosis, and detection of HCC at an early stage is critical for a favorable clinical outcome. No simple reliable non-invasive marker has been available till now. B2M, a non-glycosylated polypeptide composed of 99 amino acids, is one of the components of HLA class I molecules on the surfaces of all nucleated cells. It has been reported that the level of serum B2M is elevated in patients with chronic hepatitis C and HCV-related HCC when compared to HCV-negative patients or healthy donors. Determining the clinical utility of serum B2M as a marker for disease progression in Egyptian patients with HCV related chronic hepatitis, cirrhosis and hepatocellular carcinoma was the aim of the present study. Materials and Methods: In this analytical cross sectional study 92 participants were included in 4 equal groups: Group (1) non cirrhotic chronic HCV; Group (2) HCV related liver cirrhosis; Group (3) HCC on top of HCV,; and Group (4) healthy controls. History taking, clinical examination, routine labs and abdominal ultrasound were conducted for all patients, PCR and Metavir scores for group (1) patients, and triphasic CT abdomen and AFP for Group (3) patients. B2M levels were measured in serum with a fully-automated IMX system. Results: The mean serum B2M level of Group (1) was $4.25{\pm}1.48{\mu}g/ml$., Group (2) was $7.48{\pm}3.04$, Group (3) was $6.62{\pm}2.49$ and Group (4) was $1.62{\pm}0.63$. Serum B2M levels were significantly higher in diseased than control group (p<0.01) being significantly higher in cirrhosis ($7.48{\pm}3.04$) and HCC groups ($6.62{\pm}2.49$) than the HCV group ($4.25{\pm}1.48$) (p<0.01). There was a significant correlation between B2M Level and ALK, total and direct bilirubin and INR (p<0.05), and a significant inverse correlation between B2M level and albumin, total proteins, HB andWBCS values (p<0.05). There was no significant correlation between B2M level and viral load or Metavir score, largest tumour size or AFP (p>0.05). The best B2M cut-off for HCV diagnosis was 2.6 with a sensitivity of 100%, a specificity of 92%, a positive predictive value (PPV) of 97% and a negative predictive value (NPV) of 100%. The best B2M cut-off for HCC diagnosis was 4.55 which yielded sensitivity, specificity, positive predictive value, negative predictive values of 74%, 62%, 39.5, 87.8% respectively (p-value <0.01) while best cut-off for cirrhosis was 4.9, with sensitivity 74 % and specificity 74%.The sensitivity for HCC diagnosis increased upon B2M and AFP combined estimation to 91%, specificity to 79%, NPV to 95% and accuracy to 83%. Conclusions: Serum B2M level is elevated in HCV related chronic liver diseases and may be used as a marker for HCV disease progression towards cirrhosis and carcinoma.